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Abstract
Background: The lack of availability of appropriate medicines for children is an extensive and well known
problem. Paediatricians and Physicians who take care of the paediatric population are primarily exposed to cope
with this negative situation very often as more than half of the children are prescribed off-label or unlicensed
medicines.
Discussion: Medicinal products used to treat this population should be subjected to ethical research of high
quality and be explicitly authorised for use in children as it happens in adults. For that reason, and following the
US experience, the European Paediatric Regulation has been amended in January 2007 by the European
Commission. The objective of the Paediatric Regulation is to improve the development of high quality and
ethically researched medicines for children aged 0 to 17 years, to facilitate the availability of information on the
use of medicines for children, without subjecting children to unnecessary trials, or delaying the authorisation of
medicines for use in adults.
Summary: The Paediatric Regulation is dramatically changing the regulatory environment for paediatric medicines
in Europe and is fuelling an increased number of clinical trials in the paediatric population. Nevertheless, there are
some risks and pitfalls that need to be anticipated and controlled in order to ensure that children will ultimately
benefit from this European initiative.
Background
Children in Europe represent more than 20% of the Eur-
opean population, with about 100 million people aged
less than 19 years.
The lack of specific drugs and labelling recommenda-
tion for the paediatric population is a long-standing
worldwide problem and evidence-based prescribing for
children is compromised by lack of satisfactory data on
many drugs: 50% to 75% of medicines used in children
have not been studied adequately in the paediatric
population [1-4].
Although before a medicinal product for human use is
marketed, it has to have undergone extensive studies to
ensure its quality, safety and efficacy for use in the tar-
get population, many drugs given to children have not
been tested in this specific population at all [5]. The
barriers to undertaking proper research on children’s
drugs development are long standing and include: the
cost of studies compared with the size of the potential
market which implies that conducting research on medi-
cines for children is often financially unrewarding for
the pharmaceutical companies; difficulties in trial design
(i.e., small numbers of eligible patients and lack of
appropriate age-matched controls); time taken to com-
plete studies in children as compared in adults; long
approval processes; unique and complex ethical issues
surrounding research on children; assessment of risk-
benefit in those who cannot provide consent for them-
selves. Paediatric clinical trials of new drugs are often
started many years after the drugs were tested in adults
and involve testing at arbitrary doses and schedules on
the basis of scaled down versions of those used in
adults. By this time the drugs are already off-patent and
the financial incentive for the pharmaceutical company
to be involved in this phase of development will have
lapsed [6]. A drug can be licensed for use as a medicine
* Correspondence: f.rocchi@aifa.gov.it; paolo.paolucci@unimore.it
1Ufficio Informazione e Comunicazione - Agenzia Italiana del Farmaco (AIFA), Via
del Tritone, 181 - 00187 Roma, Italy
2Dipartimento Integrato Materno Infantile - Pediatria Generale e Specialistica
- Pediatria ad Indirizzo Oncologico - Azienda Ospedaliera Universitaria,
Policlinico di Modena, Via del Pozzo, 71, 41100 Modena, Italy
Full list of author information is available at the end of the article
Rocchi et al. Italian Journal of Pediatrics 2010, 36:56
http://www.ijponline.net/content/36/1/56 ITALIAN JOURNAL 
OF PEDIATRICS
© 2010 Rocchi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
with indications, doses and side-effect warnings just if
evidence for the safety, efficacy and acceptable
risk/benefit exists. Nevertheless, prescribing can also be
unlicensed (i.e. the medicine is given as a liquid whereas
the licence is for a tablet) or off-label, that means out-
side the terms of the licence (i.e. a different indication
or different dose for a different age group). For oral
drugs, a formulation suitable for very young children
who are unable to swallow tablets or capsules is often
unavailable. This unavailability means clinicians have
had to improvise the administration of such drugs to
these children, with unknown pharmacokinetic conse-
quences. More than half of prescriptions for children
overall, more than 80% for children with cancer and
about 90% of prescriptions for neonates are for medi-
cines which have not been licensed for that use [6-9].
Although there may be concerns in conducting trials in
the paediatric population, this has to be balanced by the
ethical issues related to giving medicines to a population
in which they have not been tested and therefore their
effects, positive or negative, are unknown. Paediatricians
very often face the dilemma of whether it is more
unethical to prescribe a drug that has not been studied
for children or to deny a potential useful treatment to a
sick child. The result is that Physicians frequently pre-
scribe marketed medicines to children on the basis of
clinical practice and medical knowledge, without any
chance to address questions concerning the risk of
underdosing or overdosing the substance as well any
appropriate consideration about early and even more
late side effects.
Market forces alone have proven insufficient to stimu-
late adequate research aimed at specific development
and authorisation of medicinal products for the paedia-
tric population. Problems resulting from the lack of sui-
tably adapted medicinal products for children include
inadequate dosage information which leads to increased
risks of adverse reactions including death, ineffective
treatment through under-dosage, non-availability to the
paediatric population of therapeutic advances, suitable
formulations and routes of administration, as well as use
of master or officinal formulations to treat the paediatric
population which may be of poor quality. Children of
different ages are vulnerable groups with specific devel-
opmental, physiological and psychological differences
from adults, which make age and development related
research of medicines particularly important. In terms of
both public health and ethics, it is clearly preferable to
test medicines in children, in a safe and controlled pae-
diatric clinical trial environment, where the individual
child is protected, than to prescribe and use medicines
in children never designed and evaluated for this parti-
cular use.
All these aspects have represented the ground for the
development of the Paediatric Regulation (EC) N° 1901/
2006 [10] entered into force on 26th January 2007. This
regulation applies, in its present form, in each member
state on the very day of its publication, without any
need for implementation in national laws, as opposed to
a European Directive, such as the Clinical Trial Direc-
tive (European Union Directive 2001/20/EC) [11].
Adoption of the Paediatric Regulation followed years
of preparation. The discussions around the drafts were
mostly based on the experience of the US that imple-
mented similar but not identical measures in 1997, pro-
viding incentives for the development of paediatric
medicines [12].
In December 2000, the European Parliament voted a
resolution addressing the need for better medicines for
children in Europe and asking the Commission to pre-
pare a new regulation. Members of the European Parlia-
ment considered that there was indeed a health issue to
be addressed and resolved at the EU level. Six years
later, the EU regulation was published. Through the
establishment of a framework of rewards, incentives,
and obligations for pharmaceutical companies, the legis-
lation aims to encourage the development of medicines
appropriately tested, authorized, and formulated for use
in children. This European law is going to impact signif-
icantly access to new drugs for children. By considerably
changing the landscape of drug development for chil-
dren, the law will provide an opportunity to make
further progress in the cure and quality of cure of chil-
dren. However, there are some risks and pitfalls that
need to be anticipated and controlled in order to ensure
that children will ultimately benefit from the European
initiative in the most broaden way.
Discussion
The Paediatric Regulation
The objective of the Paediatric Regulation is to improve
the health of children in Europe by facilitating the devel-
opment and availability of medicines for children aged 0
to 17 years. The first aim of the Paediatric Regulation is
to make medicines available for children that means
changing the way in which medicines are developed.
Increasing the development of medicines for children is
to be reached by ensuring that they are subject to high
quality research, to avoid, at the same time, unnecessary
clinical trials in children and not delaying the authoriza-
tion of medicines for the adult population. In particular,
developing medicines for children should be performed
in the relevant population subsets including the neonate
as well as children with cancer, which is still the first
cause of death in the paediatric age due to diseases.
These particular subsets are the most exposed to medi-
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cines that have neither been tested nor fully assessed.
Developing medicines in children should also consider
ethical aspects as the vulnerability of children. This is
why there is the possibility of waivers of the develop-
ment of a medicinal product for children when the
medicine is potentially harmful or ineffective, when its
development would not bring any significant therapeutic
benefit to children, and obviously, when the disease to
be treated does not occur in children.
The new key element of the Regulation is the early
involvement of a pharmaceutical company in the
research and development programme of a medicinal
product by the requirement to receive an agreement on
the proposed process for a new medicinal product, the
so called Paediatric Investigational Plan (PIP).
This contains two elements either to get a waiver or
an agreement on the clinical trials, and, if necessary, a
deferral in children to be included in the development
programme (PIP). This is in order to ensure that the
necessary data are generated determining the conditions
in which a drug may be authorised to treat the paedia-
tric population. The timing and the measures proposed
to assess quality, safety and efficacy in all subsets of the
paediatric population that may be concerned shall be
presented in a PIP. Furthermore, any measures to adapt
the formulation of the medicinal product for its use in
the paediatric population shall be included.
Pharmaceutical companies are asked to prepare and
submit a PIP at the end of phase I or II pharmacological
studies. Once approved by the European Medicines
Agency (EMA), the PIP should be undertaken to gener-
ate paediatric data that will eventually be submitted in
the application.
Every PIP presented by industry must be submitted to
the Paediatric Committee (PDCO) of the European
Medicines Agency (EMA), a new Committee composed
by paediatric experts from all over Europe and created
as stated in the Regulation.
The PDCO has been operational with 27 members,
even before finalisation of the appointment by the Eur-
opean Commission of the further 6 members represent-
ing healthcare professionals and patients’ associations.
The PDCO assesses paediatric investigation plans and
provides advice. All information is made public on the
EMA website. In addition, specific measures have been
or are in the process of being implemented by the EMA
such as an inventory of paediatric needs, the creation of
a network of paediatric networks to facilitate the con-
duct of high-quality paediatric clinical studies and the
preparation of guidelines.
Since its establishment in July 2007 the PDCO has
assessed a large numbers of procedures: by September
2009, 564 validated PIPs/waivers have been submitted
by pharmaceutical companies covering nearly 870
indications. PDCO approved 294 applications (i.e. relat-
ing to full waiver, and PIP, including potential deferral)
covering more than 20 therapeutic areas (Table 1).
When needed, the PDCO has the power to ask the
company for modifications or additional information at
a later date; this especially because the PIP should be
submitted at such an early point in the development
process and some aspects will be preliminary. Once
received the PIP, PDCO must consider whether or not
any proposed studies will be of significant therapeutic
benefit to the paediatric population. If not, the PDCO
itself will impose a waiver from the requirement to pro-
vide data from a PIP (for lack of safety or efficacy or sig-
nificant therapeutic benefit over existing treatments).
Approval of the PIP by PDCO is necessary in order to
gain both the marketing authorization and the financial
benefits. If a PIP is not approved then a pharmaceutical
company can resubmit it, and an additional appeal pro-
cess exists through the European courts.
In addition, to the scrutiny of PIPs, the PDCO has
several other tasks mandated by the regulation and it is
especially contributing to other aspects of paediatric
drug development such as guidance and reflection on of
innovative methods of development.
In order to avoid unnecessary and unethically repeti-
tion of trials in children, paediatric development is
addressed globally through a close cooperation with the
US Food and Drug Administration (FDA) and other
regions. Monthly teleconferences take place between the
EMA and the FDA.
Considering that for the first time, companies will be
required to study medicines in the paediatric population
and develop age-appropriate formulations, the Regulation
includes a system of rewards and incentives, to stimulate
paediatric drugs development and to reward the industry
for conducting the obligatory investigation programmes.
When an agreed PIP is completed and all the informa-
tion has been submitted to the regulatory authorities,
the medicinal product will be granted an extra 6 months
patent protection (extension of the duration of its Sup-
plementary Protection Certificate [SPC]), which repre-
sents the reward to pharmaceutical companies. This
extension will be granted whether or not the data sup-
port a paediatric indication. A compound is usually pro-
tected for 7 years during which no generic compound
can be marketed and the pharmaceutical company can
thus enjoy returns on its investments. The 6 months
extension is a substantial reward for most of the drugs
since the extended market exclusivity represents signifi-
cant benefits when the drug is sold throughout Europe.
For orphan medicinal products the incentive takes the
form of an extra two years market exclusivity.
The Regulation also establishes a new type of market-
ing authorisation, called the paediatric use marketing
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Table 1 PIPs/waivers approved by PDCO on September 2009
Therapeutic area PIPs Waivers
Anaesthesiology 1(1RW)
Bone disease 1
Cardiology 1 5
Cardiology/endocrinology/metabolism 1
Cardiovascular diseases 18 16
Dermatology 6 2
Diagnostic and other 1 1
Endocrinology 1
Endocrinology and metabolism 6 5
Endocrinology/gynaecology/ 3 3
Endocrinology/gynaecology/fertility/metabolism 18 16
Gastroenterology 1
Gastroenterology Haemostaseology 6
Gastroenterology Hepatology 6 (1RP) 2
Gastroenterology-Hepatology Dermatology Immunology-Rheumatology-Transplantation 1
Gastroenterology-Hepatology/Immunology 1
Gynaecology 1
Haemathology 3
Haemathology/haemostaseology 1
Hepatology 1
Immunology 3 1
Immunology/rheumatology/transplantation 10 1
Infectious diseases 24 1
Metabolism 5
Nephrology 1
Neonatology - paediatric intensive care 1
Neurology 9 5
Nutrition 2
Oncology 16 13
Oncology - Endocrinology-Gynaecology-Fertility-Metabolism - Immunology-Rheumatology-Transplantation 1
Ophthalmology 3 6
Oto-rhino-laryngology 1
Oto-rhino-laryngology - Pneumology - Allergology - Dermatology 1
Pain 9 7
Pain and neurology 1
Pneumology 7 4
Pneumology - allergology 5 3 (2RW)
Psychiatry 3 1
Rheumatology 2
Urology 2
Uro-Nephrology 2 2
Vaccine 20 2
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authorisation (PUMA), intended to stimulate the devel-
opment of off-patent products for use in the paediatric
population. Only medicines that are intended solely for
use in children will be eligible for a PUMA. Indeed,
there is still a need for additional paediatric information
on off-patent medicines as most of these compounds
are in the public domain, are still widely used daily in
children of all age groups, have not been adequately
tested in the paediatric population. The PUMA is the
specific instrument created by the Regulation, which can
be granted for off-patent medicine that provides addi-
tional information according to the needs identified by
the EMA. The Paediatric Regulation includes provisions
for funding of research into off-patent medicines. Public
funding is necessary as off-patent medicines are of little
commercial interest for pharmaceutical companies. The
PDCO has recently updated a list of priorities that indi-
cates the areas and products that require paediatric
development and should have potential for funding by
the European Commission (Directorate-General
Research, Brussels, Belgium). Six projects have obtained
funding in the first exercise in 2007 [13]. Also the 7th
European Framework Programme launched specific calls
for proposals to support studies on these old drugs
which are unlikely to be funded by large pharmaceutical
companies. Public and public/private consortia are cur-
rently funded to study drugs in agreement with the
priority list established by the EMA. Although they are
relatively weak so far it is hoped that the incentives
associated with a PUMA will encourage the develop-
ment of new paediatric formulations for these old
products.
The second main pillar of the Paediatric Regulation is
to increase paediatric research. Clinical trials in the pae-
diatric population require specific expertise, in some
cases specific methodology and specific facilities, and
should be carried out by appropriately trained investiga-
tors. Two main approaches are being implemented in
order to facilitate this aspect: the creation of an Eur-
opean Network of Paediatric Research, and research
funding. The EMA is responsible for establishing a net-
work of existing networks, centres and investigators of
paediatric research. The strategy for the establishment
of the European Network has now been adopted and
published [14,15]. The network’s objectives are to coor-
dinate studies relating to paediatric medicinal products,
to build up the necessary scientific and administrative
competences at European level, in order to avoid dupli-
cation of studies and testing in children.
EMA is supporting the development of this strategy by
providing free paediatric scientific advice from, informa-
tion tools (i.e., an inventory of therapeutic needs, infor-
mation on new product labelling requirements, a public
database of clinical trials), enhanced safety monitoring
for marketed products concerning the obligation to
include long-term follow-up of adverse drug reactions
(ADRs) and the requirement for post marketing data for
pharmacovigilance.
The benefits of a European Network of paediatric
research include technical and/or administrative compe-
tences in the performance of paediatric clinical trials
through effective collaboration. They also include avoid-
ing duplication of work and efforts, making the use of
facilities more efficient and profitable, developing com-
mon methods of working with special attention to qual-
ity assurance. Additional benefits are the facilitation of
recruitment of patients, and avoiding unnecessary stu-
dies in children. The EU network should serve as a tool
for industry to perform trials with children in keeping
with the PIP.
The third aim of Regulation is transparency and infor-
mation. Through increased availability of information,
the safe and effective use of medicinal products for chil-
dren can be increased so promoting public health. In
addition, availability of this information will help pre-
vent the duplication of studies in children avoiding
unnecessary studies. One of the measures is making all
paediatric trials included in the European database
(EudraCT) accessible to the public both for protocol
and results-related information. The increase of trans-
parency in respect to clinical trials in children in all
phases of the progress, beginning from the planning and
recruiting of patients to the on-going and finalised stu-
dies, is another target of the Regulation. All decisions of
the EMA on PIPs, deferrals or waivers of the paediatric
development have to be made public and are routinely
published on EMA website [16]. Moreover where
authorisation is granted, the results of all those paedia-
tric studies, any waivers or deferral, shall be included in
the Summary of Product Characteristic and, if appropri-
ate, in the Patient Leaflet of the medicinal product,
whether or not all the paediatric indications concerned
were approved by the competent authority.
Considerations and expectations
Thanks to the Paediatric Regulation, safety and efficacy
studies in the paediatric population have become man-
datory for any drug likely to be used to treat children
for which a new marketing authorisation or marketing
authorisation variation is requested, as well as incentives
for off-patent drugs. The regulation also requires that
data for long-term follow-up of ADRs are included in
any clinical trials that take place. Marketing authorisa-
tion variations are especially relevant to many drugs that
are only authorised for use in adults, but which are fre-
quently used in children.
This regulation is a remarkable step forward, because
for the first time in Europe it is a regulation that is
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provided by law and provides direct economic support
for paediatric clinical trials and indirect support for
pharmaceutical industries.
The effect of the new regulation is expected to stimu-
late high-quality research and provide robust informa-
tion on paediatric drugs to increase the availability of
such drugs to children. This regulation aims to keep
ineffective treatment, incorrect dosing and ADRs to a
minimum; to reduce hospitalisations and deaths; to
improve quality of life; and to provide economic bene-
fits. The expectation of this regulation is that it will pro-
vide the paediatric population with safe access to older
drugs and early access to newer, safer, and more tar-
geted treatments.
The implementation of the European Regulation on
medicines for paediatric use means also that in both the
Europe and the USA, there is now a similar approach to
paediatric drug development. Both require pharmaceutical
companies to consider the needs of children and to carry
out appropriate studies, and both provide financial
rewards to companies who comply. It would be reasonable
to assume that manufacturers will adopt strategies to
ensure that new medications will pass both sets of regula-
tions in parallel, to minimize time and maximize profits.
An integrated overview procedure is also included in
the new European Regulation, with the European Com-
mission charged with writing a report on the positive
and negative aspects of its implementation, including
the economic and public health effects. At the time
being it is not always possible to foresee how a new
piece of legislation will affect a marketplace, nevertheless
it appears that Europe has learnt from the initial US
experience, finally giving the development of drugs for
children a legal status. This should allow greater and
safer drug development for this vulnerable previously
neglected population.
Summary
To tackle the lack of specific drugs developed for pae-
diatric population a new Paediatric Regulation entered
into force in the European Union on 26th January 2007.
The objective of the Paediatric Regulation is to improve
the development of medicines of high quality and ethi-
cally researched for children aged 0 to 17 years, to
improve the availability of information on the use of
medicines for children, without subjecting children to
unnecessary trials or delaying the authorisation of medi-
cines for use in adults.
The Regulation has provided the establishment in Eur-
ope of a mandatory Paediatric Investigation Plan (PIP)
which is legally binding for manufacturers willing to
seek marketing authorisation with a systems of incen-
tives and rewards, and the establishment of a permanent
Paediatric Committee at the EMA. The Regulation also
establishes a new type of marketing authorisation, called
the Paediatric Use Marketing Authorisation (PUMA),
intended to stimulate the development of off-patent pro-
ducts for use in the paediatric population. The Regula-
tion is also aimed to the creation of an European
Network of paediatric research, and research funding.
The Paediatric Regulation is dramatically changing the
regulatory environment for paediatric medicines in Eur-
ope and is fuelling an increased number of clinical trials
in the paediatric population.
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